CrossAssetDataThe Company File
···
AMPH

Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Rancho Cucamonga, CA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $720 million and a profit of $98 million (its filed statements).

Product business Pharmaceutical Preparations Rancho Cucamonga, CA filings since 2005 9 of 9 filed
Ask the desk about AMPH → Compare AMPH with INVA → Price chart on TradingView ↗ Full EDGAR file ↗ Watch AMPH →

Sector peers: INVACOLLACADLGND

6.5/10headline grade
vs its business-model standard
7.7/10past 7.4/10present 4.1/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2834, Pharmaceutical Preparations); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 6.5 out of ten, 9 of 9 metrics filed: past 7.7 out of ten, present 7.4 out of ten, future 4.1 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 8.2 out of ten. No warning events in its filings since 2017. 82nd percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 7.3 out of ten. +12.2% a year over 10 filed years; profitable in 9 of 10. 73rd percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 7.7 out of ten. Share count shrank 2.8% a year. 40% of cash flow returned. Insiders: 12 sales, 0 purchases. 77th percentile among 80 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Financial health (present): 6.7 out of ten. ROE 12%: 12¢ of profit per shareholder dollar. Leverage 52%: owes 52¢ per asset dollar. 67th percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 7.5 out of ten. top 25% of 314 in its family; net margin 13.6%. 75th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 8.5 out of ten. top 15% of 315 in its family for leadership; chief executive since 2014. 85th percentile among 315 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
  • Room to expand (future): 3.3 out of ten. bottom 33% of 272 in its family for room to expand. 33rd percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 5.8 out of ten. top 42% of 307 in its family for growth drivers. 58th percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 3.1 out of ten. bottom 31% of 234 in its family for expectations against reality. 31st percentile among 234 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2026-02-26 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-06 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-06 (on EDGAR). Newest filing: Form 4, 2026-09-23. Filings on record since 2005. Read from EDGAR 2026-10-12.

Where the revenue comes from

By geography: United States 95%, France 5%, China under 1%. As tagged in its annual report (Form 10-K, filed 2026-02-26).

Who runs it

Zhang, Jack Y. (CEO & CHIEF SCIENTIFIC OFFICER); Luo, Mary Z. (COO, Chief Scientist, Chairman); Peters, William J (CFO, EVP & TREASURER); Zhou, Rong (SENIOR EVP, PRODUCTION CENTER); Gerst, Diane G. (EVP, QA & Regulatory Affairs); Liawatidewi, Yakob (EVP CORP ADMIN CENTER); Prins, Richard K (director); Pierce, Anthony T (director); Deflin, Gayle (director); Gaugh, David Russell (director); and 3 more. 13 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.